הלוואות ואשראי לטווח ארוך של החברה: Teva (TEVA)

Teva Pharmaceutical Industries (TEVA) relies on a global pharmacy network and large-scale generic production. Revenues are based on mass sales of non-proprietary drugs and CNS innovations. Restructuring and the launch of Austedo have ensured a stable cash flow. The amount of the issuer's long-term liabilities demonstrates the maturity of liabilities, where the 12.09 indicator expresses the metric level, allowing for an assessment of the company's debt load.

Long-term debt measures the total volume of borrowed funds with a maturity of more than one year, determining financial stability and the cost of capital. A decrease in this metric signals deleveraging and an increase in the issuer's creditworthiness. By analyzing the volume of an issuer's long-term liabilities, an investor assesses the pace at which the business is shedding its debt burden. For Teva Pharmaceutical Industries (TEVA), this is critically important as the company is undergoing a stage of rigorous restructuring following an unsuccessful acquisition.